FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308187414> ?p ?o ?g. }

• W4308187414 endingPage "264" @default.
• W4308187414 startingPage "263" @default.
• W4308187414 abstract "Dear Editor,&#x0D; Cancer is a foremost death cause in each country and a substantial hindrance to improving life expectancy, accounting for more than 10 million fatalities in 2020, or around one in every six fatalities [1]. Oral cancer is among the leading causes of cancer-related mortality in developing countries. Oral squamous cell carcinoma (OSCC) is a widespread type of malignancy associated with tobacco usage and human papilloma virus infection. The majority of people are diagnosed with cancer at an advanced stage, the 5-year survival rate for OSCC patients is only around 50%. Despite biological and technological advances, in recent decades, the prognosis for OSCC has not improved, and its occurrence has increased. Identification of biomarkers that can be utilized to establish an early diagnosis or predict tumor growth is enabled by determining which molecular pathways are disrupted [2].&#x0D; MicroRNAs, which can serve as both oncogenes and tumor-inhibiting factors, are misaligned in a wide range of cancers [3]. These are short, noncoding RNAs that affect protein expression following transcription at the post-transcriptional level. MicroRNAs play a vital role in proliferation, differentiation, apoptosis, immune response, and angiogenesis, among other things in the pathogenesis of cancer. Multiple researchers have documented that specific microRNAs are frequently down regulated in cancers, implying that they operate as tumor suppressors by targeting many oncogenes. According to research conducted by O’Brien et al, altering levels of microRNAs expression can improve chemotherapeutic efficacy [4]. In recent decades, several researches have linked metastasis, survival, and recurrence of OSCC patients to miRNA expression [5].&#x0D; MicroRNA-31, a gene on chromosome 9p21.3, was one of the first mammalian microRNAs discovered. Several studies have been conducted to evaluate the functions of miR-31 in carcinogenesis and the progression of OSCC. A prior clinical investigation conducted by Liu et al. [6] revealed that miR-31 levels in plasma were considerably increased in patients with OSCC when compared to age and gender-matched control participants. Several studies show that miR-31 performs a role in cancer etiology and aggressiveness via altering target genes. According to reports, miR-31 regulates a number of genes, including fibronectin type III domain containing 5, special AT-rich sequence-binding protein-2, large tumor suppressor kinase 2 (LATS2), tensin 1, AT-rich interaction domain 1A, and hypoxia-inducible factor-1 [7]. The concentration of miR-31 expression in serum, urine, saliva and organ tissue can be utilized as a diagnostic and predictive biomarker for a variety of malignancies [8].&#x0D; A recent investigation by Chou et al. [9] found that miR-31 levels were significantly raised in OSCC cells and tumor tissues, and that the miR-31 gene locus was necessary to initiate oncogenesis in OSCC. Upregulation of miR-31 contributes to the formation of OSCC by interacting with certain genes and signaling pathways that impact cancer cell cycle, epithelial-mesenchymal transition and cell proliferation. miR-31 forms a complex network with direct target genes (such as RHOA, FIH, ACOX1, VEGF, SIRT3, LATS2, KANK1, and NUMB) and initiates several signaling pathways including the ERK-MMP9 cascade, the Hippo pathway, Wnt signaling, and the MCT1/MCT4 regulatory cascade [10]. MiR-31 interacts with a number of proteins and pathways that are crucial in OSCC and it is overexpressed in plasma, saliva, and OSCC tumor tissue. However, more research is needed to fully comprehend the molecular mechanisms by which miR-31 drives OSCC malignancy, paving the way for the development of miR-31 based diagnostic, prognostic, and predictive biomarkers for OSCC." @default.
• W4308187414 created "2022-11-09" @default.
• W4308187414 creator A5038224504 @default.
• W4308187414 creator A5038421157 @default.
• W4308187414 creator A5071524610 @default.
• W4308187414 creator A5080532365 @default.
• W4308187414 creator A5083129785 @default.
• W4308187414 creator A5088710722 @default.
• W4308187414 date "2023-05-26" @default.
• W4308187414 modified "2023-10-18" @default.
• W4308187414 title "MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS" @default.
• W4308187414 doi "https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18569" @default.
• W4308187414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36325699" @default.
• W4308187414 hasPublicationYear "2023" @default.
• W4308187414 type Work @default.
• W4308187414 citedByCount "0" @default.
• W4308187414 crossrefType "journal-article" @default.
• W4308187414 hasAuthorship W4308187414A5038224504 @default.
• W4308187414 hasAuthorship W4308187414A5038421157 @default.
• W4308187414 hasAuthorship W4308187414A5071524610 @default.
• W4308187414 hasAuthorship W4308187414A5080532365 @default.
• W4308187414 hasAuthorship W4308187414A5083129785 @default.
• W4308187414 hasAuthorship W4308187414A5088710722 @default.
• W4308187414 hasConcept C104317684 @default.
• W4308187414 hasConcept C121608353 @default.
• W4308187414 hasConcept C126322002 @default.
• W4308187414 hasConcept C143998085 @default.
• W4308187414 hasConcept C145059251 @default.
• W4308187414 hasConcept C2779013556 @default.
• W4308187414 hasConcept C2779399171 @default.
• W4308187414 hasConcept C2780394083 @default.
• W4308187414 hasConcept C2781197716 @default.
• W4308187414 hasConcept C502942594 @default.
• W4308187414 hasConcept C54355233 @default.
• W4308187414 hasConcept C60644358 @default.
• W4308187414 hasConcept C71924100 @default.
• W4308187414 hasConcept C86803240 @default.
• W4308187414 hasConceptScore W4308187414C104317684 @default.
• W4308187414 hasConceptScore W4308187414C121608353 @default.
• W4308187414 hasConceptScore W4308187414C126322002 @default.
• W4308187414 hasConceptScore W4308187414C143998085 @default.
• W4308187414 hasConceptScore W4308187414C145059251 @default.
• W4308187414 hasConceptScore W4308187414C2779013556 @default.
• W4308187414 hasConceptScore W4308187414C2779399171 @default.
• W4308187414 hasConceptScore W4308187414C2780394083 @default.
• W4308187414 hasConceptScore W4308187414C2781197716 @default.
• W4308187414 hasConceptScore W4308187414C502942594 @default.
• W4308187414 hasConceptScore W4308187414C54355233 @default.
• W4308187414 hasConceptScore W4308187414C60644358 @default.
• W4308187414 hasConceptScore W4308187414C71924100 @default.
• W4308187414 hasConceptScore W4308187414C86803240 @default.
• W4308187414 hasIssue "3" @default.
• W4308187414 hasLocation W43081874141 @default.
• W4308187414 hasLocation W43081874142 @default.
• W4308187414 hasOpenAccess W4308187414 @default.
• W4308187414 hasPrimaryLocation W43081874141 @default.
• W4308187414 hasRelatedWork W2004339436 @default.
• W4308187414 hasRelatedWork W2042474810 @default.
• W4308187414 hasRelatedWork W2075734225 @default.
• W4308187414 hasRelatedWork W2123707479 @default.
• W4308187414 hasRelatedWork W2127463799 @default.
• W4308187414 hasRelatedWork W2561802298 @default.
• W4308187414 hasRelatedWork W31401667 @default.
• W4308187414 hasRelatedWork W3152246802 @default.
• W4308187414 hasRelatedWork W638153814 @default.
• W4308187414 hasRelatedWork W73242545 @default.
• W4308187414 hasVolume "44" @default.
• W4308187414 isParatext "false" @default.
• W4308187414 isRetracted "false" @default.
• W4308187414 workType "article" @default.